4.88 USD
▼-0.17-3.37%
2026-09-15
市值
$381.63M
市盈率
—
EPS
-2.56
股息率
—
52 周区间
4.72 – 14.87
成交量
629.20K
Beta
0.39
目标价
24.73
52W 低 4.7252W 高 14.87
价格走势
公司简介
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical...